- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03774979
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
November 6, 2022 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Phase I, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications
The main purpose of this study is to assess the safety and tolerability of SHR-1701 at different dose levels.
Study consists of dose-escalation part and an expansion part in subjects with metastatic or locally advanced solid tumors.
Study Overview
Detailed Description
This is a Phase I, open-label, multiple-ascending dose trial.
Study consists of dose-escalation part in subjects with metastatic or locally advanced solid tumors, and expansion part with selected indications.
Study Type
Interventional
Enrollment (Actual)
193
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing Chest Hospital,Capital Medical University-Integrated Department
-
Beijing, China
- Tumor Hospital of the Chinese Academy of Medical Sciences
-
Chongqing, China
- ChongQing Cancer Hospital-gynecologic oncology
-
Chongqing, China
- Chongqing Cancer Hospital
-
-
Anhui
-
Hefei, Anhui, China
- Anhui Chest Hospital-Departmen of Tumor Radiotherapy
-
-
Guangzhou
-
Guangzhou, Guangzhou, China
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine-Cancer Center
-
-
Henan
-
Xinxiang, Henan, China
- Xinxiang Central Hospital-Department of Respiratory Physicians
-
Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University-Department of Medical Oncology
-
-
Hunan
-
Changsha, Hunan, China
- Cancer Hospital of Hunan Province
-
Changsha, Hunan, China
- Hunan Cancer Hospital-Gynecologic Oncology
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jangsu Cancer Hospital
-
Suzhou, Jiangsu, China, 215006
- The First Rffiurted Hospital of Soochow University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The first affiliated Hospital of Nanchang University
-
-
Liaoning
-
Shenyang, Liaoning, China
- The First Hospital of China Medical University-Department of Oncology
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Qilu Hospital of Shandong University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able and willing to provide signed informed consent form, and able to comply with all procedures.
- Histologically or cytologically proven metastatic or locally advanced solid tumors.
- Male or female subjects aged 18-75 years.
- Life expectancy >= 12 weeks as judged by the Investigator.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry.
- Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Adequate hematological, hepatic and renal function as defined in the protocol
Other protocol-defined inclusion criteria could apply.
Exclusion Criteria:
- Prior therapy with an anti-PD1, anti-PD-L1, anti-CTLA-4 or a TGFb inhibitor.
- Anticancer treatment within 28 days before the first dose of study drug.
- Major surgery within 28 days before start of trial treatment.
- Systemic therapy with immunosuppressive agents within 7 days prior to the first dose of study drug; or use any investigational drug within 28 days before the start of trial treatment.
- With any active autoimmune disease or history of autoimmune disease.
- With active central nervous system (CNS) metastases causing clinical symptoms or requiring therapeutic intervention.
- Clinically significant cardiovascular and cerebrovascular diseases
- History of immunodeficiency including seropositive for human immunodeficiency virus (HIV), or other acquired or congenital immunedeficient disease, or any active systemic viral infection requiring therapy.
- Previous malignant disease (other than the target malignancy to be investigated in the trial) within the last 2 years. Subjects with history of cervical carcinoma in situ, superficial or non-invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent are NOT excluded.
- Receipt of any organ transplantation, including allogeneic stem-cell transplantation
Other protocol-defined exclusion criteria could apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-1701
intravenous infusion
|
Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose escalation part: Safety and tolerability of SHR-1701 in advanced malignancies.
Time Frame: Up to 3/4 weeks.
|
Number of Subjects who occurs dose-limiting toxicity (DLTs).
|
Up to 3/4 weeks.
|
Clinical expansion Part: Objective Response Rate(ORR)
Time Frame: Up to 6 weeks
|
ORR is define as the percentage of participants in the analysis population who havea Complete Response(CR:Disappearance of all target lesions)or a Partial Response(PR :30% decrease in the sum of diameter of target lesions) per RECIST 1.1.
|
Up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical expansion Part: Safety of SHR-1701
Time Frame: Up to 4 weeks after last treatment
|
Number of subjects who occurs treatment-related Adverse Events(AEs)
|
Up to 4 weeks after last treatment
|
Clinical expansion Part: Disease Control Rate(DCR) per RECIST1.1
Time Frame: Up to 6 weeks
|
DCR is define as the percentage of participants in the analysis population who have a CR,PR or SD per RECIST 1.1.
|
Up to 6 weeks
|
Clinical expansion Part: Duration of Response (DOR)per RECIST1.1
Time Frame: Up to 6 weeks
|
DOR is define as the time from first documented evidence of CR or PR until disease progression per RECIST 1.1
|
Up to 6 weeks
|
Clinical expansion Part:Progression-free survival(PFS) per RECIST1.1
Time Frame: 12months (anticipated)
|
PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1
|
12months (anticipated)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jifeng Feng, MD, Jiangsu Cancer Institute & Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2019
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
December 10, 2018
First Submitted That Met QC Criteria
December 12, 2018
First Posted (Actual)
December 13, 2018
Study Record Updates
Last Update Posted (Actual)
November 8, 2022
Last Update Submitted That Met QC Criteria
November 6, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-1701-I-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
Clinical Trials on SHR-1701
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.WithdrawnNon-Small-Cell Lung Cancer
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingNasopharyngeal CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Shanghai Chest HospitalNot yet recruiting
-
Atridia Pty Ltd.Completed
-
Chinese PLA General HospitalRecruitingRelapsed or Refractory Hodgkin LymphomaChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingAdvanced or Metastatic Non-squamous Non-small Cell Lung Cancer
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting